| DocumentPRX-BRF-003 | TopicMethod | Published1 August 2026 | RevisionA |
1.0Summary
Simulated payer research went from novelty to product category fast. Large consultancies now sell payer "digital twins," and a wave of AI vendors will happily conjure a synthetic medical director for you. Some of this is useful. Some of it is expensive improv. The difficulty for a buyer is that both look identical in a demo, because a fluent simulation is easy and a faithful one is hard.
2.0
The one question that separates them
Ask the vendor one question. How does your simulation score against real payer decisions the model never saw?
Training data and expert review are provenance claims, and provenance is not validation. The only honest test of a synthetic payer is predictive. Hold out real, public coverage decisions from the persona's construction, run the persona against the underlying evidence, and score the agreement. If the vendor has no held-out backtest, they have no fidelity number, and if they have no fidelity number, you are buying tone of voice.
3.0
A buyer's checklist
3.1 Demand the backtest design
Which decisions were held out, how many, and were they truly excluded from construction? A model graded on decisions it studied is a memorization test.
3.2 Demand the score, per persona
An aggregate across payer types can hide a persona that fails its own archetype. Our own standard is a published score per persona, and panels have ranged 80–92% against held-out decisions; anything unscored does not sit at the table.
3.3 Demand the failure modes
A credible vendor can tell you where the simulation diverges from reality, such as novel technology categories with thin decision history, plan-specific formulary politics, and the human variance of an individual reviewer. If they claim it works everywhere, it has been tested nowhere.
3.4 Keep it in its lane
Simulation prepares you for payer engagement; the engagement itself still has to happen. Its economic value is resolving the anticipatable objections cheaply, so your real payer interactions spend their scarce minutes on questions only real payers can answer.
4.0
Why we publish our methodology
We sell a simulated panel, so this article is self-interested, and the remedy for self-interest is inspectability. Our fidelity methodology, held-out split design, and scoring standard are public, and every panel ships with its backtest scores. Hold every vendor to that bar, including us. The category will be better for it, and so will your evidence plan.
Praxa is a market access firm for medtech and life sciences companies; every deliverable ships with a verified evidence trail. Questions about how this applies to your product go to ryan@praxa.partners.
5.0Revision history
| Rev | Date | Change |
|---|---|---|
| A | 1 August 2026 | First published |
Talk to us about your pathway
A 30-minute conversation and a fixed quote from the published menu.